Sanofi to Acquire Shantha for $784 Million

Article

French drug manufacturer Sanofi Aventis will purchase the Indian vaccine company Shantha Biotechnics for $784 million.

French drug manufacturer Sanofi Aventis will purchase the Indian vaccine company Shantha Biotechnics for $784 million. This acquisition will give Sanofi a platform in India as well as access to a pipeline of new products.

Per the agreement, Sanofi's vaccine division Sanofi-Pasteur will acquire ShanH, French subsidiary of Merieux Alliance, which holds a majority stake in Hyderabad-based Shantha.

Sanofi Pasteur, Sanofi’s vaccine unit, will support Shantha’s development. Varaprasad Reddy, who founded Shantha in 1993, will continue leading the company as managing director.

Read Pharmaceutical Technology’s blog on the deal

Newsletter

Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.

Recent Videos
Junevity Co-founder & CEO, John Hoekman, PhD
DC skyline at night with view of the White House and the Washington Monument | Image Credit: © Jessica - stock.adobe.com
Daniel Fischer, Tevard
Related Content
© 2025 MJH Life Sciences

All rights reserved.